COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 1 of 1 for:    NCT03225287
Previous Study | Return to List | Next Study

Extension Study of RA101495 for Patients With PNH Who Have Completed a Zilucoplan (RA101495) Clinical Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03225287
Recruitment Status : Active, not recruiting
First Posted : July 21, 2017
Last Update Posted : June 19, 2019
Information provided by (Responsible Party):
Ra Pharmaceuticals

Brief Summary:
The purpose of this study is to enable continued access to zilucoplan (RA101495) for patients with paroxysmal nocturnal hemoglobinuria (PNH) after they complete a zilucoplan clinical study.

Condition or disease Intervention/treatment Phase
Paroxysmal Nocturnal Hemoglobinuria (PNH) Drug: Zilucoplan (RA101495) Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 28 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Open-label, Uncontrolled, Extension Study of RA101495 in Subjects With Paroxysmal Nocturnal Hemoglobinuria Who Have Completed a RA101495 Clinical Study
Actual Study Start Date : July 17, 2017
Estimated Primary Completion Date : January 2020
Estimated Study Completion Date : January 2020

Arm Intervention/treatment
Experimental: Zilucoplan (RA101495)
Subjects will continue to receive the final maintenance dose they were receiving in the qualifying study
Drug: Zilucoplan (RA101495)
Subjects will continue to receive the final maintenance dose they were receiving in the qualifying study.

Primary Outcome Measures :
  1. Adverse Events and Serious Adverse Events Profile [ Time Frame: Safety events will be assessed at each study visit through the completion of the study (approximately 2.5 years) ]
    Adverse Events and Serious Adverse Events Profile

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Completion of a qualifying Ra Pharmaceuticals sponsored zilucoplan (RA101495) PNH study
  • Evidence of ongoing clinical benefit in the opinion of the Investigator

Exclusion criteria:

  • History of meningococcal disease
  • Current systemic infection or suspicion of active bacterial infection

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03225287

Layout table for location information
United States, California
Investigative Site
Duarte, California, United States, 91010
United States, Illinois
Investigative Site
Chicago, Illinois, United States, 60612
United States, New York
Investigative Site
Manhasset, New York, United States, 11042
United States, North Carolina
Investigative Site
Durham, North Carolina, United States, 27710
United States, Texas
Investigative Site
Dallas, Texas, United States, 75390
Investigative site
Gosford, Australia
Investigative site
Melbourne, Australia
Investigative Site
Copenhagen, Denmark
Investigative Site
Helsinki, Finland
Investigative Site
Essen, Germany
Investigative Site
Ulm, Germany
Investigative Site
Budapest, Hungary
New Zealand
Investigative Site
Christchurch, New Zealand
Investigative Site
Hamilton, New Zealand
United Kingdom
Investigative Site
Leeds, United Kingdom
Investigative Site
London, United Kingdom
Sponsors and Collaborators
Ra Pharmaceuticals
Layout table for investigator information
Study Chair: Dr. Anita Hill St James' Institute of Oncology
Layout table for additonal information
Responsible Party: Ra Pharmaceuticals Identifier: NCT03225287    
Other Study ID Numbers: RA101495-01.202
2016-003523-34 ( EudraCT Number )
First Posted: July 21, 2017    Key Record Dates
Last Update Posted: June 19, 2019
Last Verified: June 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hemoglobinuria, Paroxysmal
Urination Disorders
Urologic Diseases
Urological Manifestations
Anemia, Hemolytic
Hematologic Diseases
Myelodysplastic Syndromes
Bone Marrow Diseases